GRK4 Polymorphisms Blood Pressure Response to Candesartan

• Status: Unknown status
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Military Medical University
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• men and women with mild to moderate essential hypertension in southwestern Han Chinese

Exclusion Criteria:

• subjects unwilling to participate or subjects did not have all measurement required,

• subjects who were on medications, which affect blood pressure or

• whose DNA failed to amplify and 8 with errors in Mendelian segregation